Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Kenneth Kolinsky

Brian Higgins

Kathryn Elizabeth Packman

Fei Su

Gwen Nichols

Kapil Dhingra

Richard J Lee

Brian Lestini

Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.

Combination therapy for proliferative disorders

The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.

The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.

Combination therapy

Growing community of inventors

Bloomingdale, NJ, United States of America

Kenneth Kolinsky